MAP2 and Parkinson disease: Quantification following double immunofluorescence staining for SYNJ1 and MAP2 of control and PD brain samples (Table 1) also showed no significant difference between the two groups (Supplementary Fig. 8b,c, online resource), indicating that the PD cases used in this study deviate from the abovementioned sub-group.